drugset / Trial / NCT00546351

Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

NCT00546351

Phase 3 Completed 621 enrolled UCB Pharma
NaSingle-groupOpen-labelTreatment

Summary

SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as SPM 927) in subjects with painful distal diabetic neuropathy.

Timeline

Start
2004-05
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified 50 mg
Subject Lacosamide Other / unclassified 100 mg
Subject Lacosamide Other / unclassified 600 mg